Vilnius-based healthtech company Self.co, which offers at-home allergy and food intolerance testing with personalized reports, has raised €2.56 million in combined grant and venture funding to support its expansion into new markets.
Established in 2015 by Gintautas Gylys and Tautvydas Gylys, Self.co is a digital health and diagnostics company focused on helping people understand and manage allergy-like symptoms. The firm develops proprietary molecular testing technology, including microarray-based assays that analyze 98 allergens and 220 food sensitivities from a small blood sample collected at home or in partner clinics.
Once the samples are processed in Self.co’s certified laboratories, results are combined with AI-driven analysis to generate detailed, personalized reports that guide avoidance strategies and treatment options. By controlling the entire testing process, from technology development to lab analysis, the company ensures high accuracy, affordability, and fast turnaround times, providing users with actionable insights for better health management.
“Millions of people live with allergy-like symptoms but without a real understanding of what’s causing them or what to do about it. We’ve taken advanced diagnostic technology and built a simple test system that gives anyone clear, medically valid answers without the high cost or long wait. Now the funding will help us bring our product to new markets like the UK, Ireland, Austria, and Germany, and deepen ongoing collaboration with healthcare systems in Poland and Lithuania,” explains Tautvydas Gylys, co-founder and CEO of Self.co.
The fresh round was led by Iron Wolf Capital, with participation from Coinvest, NGL Ventures, and several angel investors, alongside a €1.36 million grant from Innovation Agency Lithuania.
“As deep tech investors, we back technologies with the potential to transform established industries – and that’s exactly what Self.co is doing in allergy diagnostics and care. This is a large, fast-growing market still underserved by current solutions. Tautvydas and the team combine exceptional industry insight with strong execution, giving them a rare founder-market fit. Self.co’s platform addresses long-standing pain points for patients and clinicians, positioning the company to redefine allergy care globally. We’re proud to lead this round and support their mission to deliver meaningful healthcare innovation at scale,” claims Kasparas Jurgelionis, Managing Partner at Iron Wolf Capital.
Self.co will use the funding to enter Germany, Austria, Ireland, and the UK, while enhancing operations in Poland and Lithuania. The capital will also support the development of its proprietary testing technology and a digital health platform that integrates diagnostics, treatment, and long-term management for individuals with allergy-like symptoms.
